publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
comment
wwwthelancetcominfect
vol
juli
low
r
barcello
c
coelho
c
et
al
dengu
outlook
world
cup
brazil
earli
warn
model
framework
driven
realtim
season
climat
forecast
lancet
infect
di
publish
onlin
may
http
dx
decad
outbreak
sever
acut
respiratori
syndrom
coronaviru
sarscov
infect
world
confront
possibl
intern
spread
novel
coronaviru
middl
east
respiratori
syndrom
coronaviru
merscov
appar
origin
arabian
peninsula
merscov
associ
sever
respiratori
tract
infect
often
renal
failur
mortal
exceed
patient
admit
hospit
similar
sarscov
close
relat
bat
coronavirus
merscov
diff
erent
cellular
receptor
specifi
citi
broader
speci
rangecamel
seem
role
natur
host
saudi
arabia
sever
aff
ect
far
import
caseseith
recent
travel
transport
clinic
carehav
seen
countri
europ
africa
asia
north
america
major
nosocomi
outbreak
happen
middl
east
nonsustain
humantohuman
transmiss
event
elsewher
mani
clinic
case
like
occur
recent
surg
case
report
could
result
humantohuman
transmiss
due
chang
exposur
pattern
expans
viru
anim
reservoir
season
variat
ongo
nosocomi
cluster
increas
surveil
report
mild
asymptomat
merscov
detect
sever
merscov
diseas
occur
primarili
older
adult
particularli
men
comorbid
howev
data
diseas
pathogenesi
particularli
viral
replic
pattern
clinic
manifest
scarc
present
despit
laboratoryconfi
rmed
merscov
case
far
hand
patient
systemat
virolog
biomark
sampl
consequ
mani
unansw
question
regard
site
infect
pathogen
dynam
innat
adapt
immun
respons
host
genet
factor
prolong
viral
replic
lower
respiratori
tract
extra
pulmonari
viru
detect
sever
lung
injuri
respiratori
failur
often
renal
failur
notabl
featur
suggest
eff
ectiv
antivir
regimen
perhap
combin
immunomodulatori
agent
would
provid
clinic
benefi
although
support
care
central
clinic
manag
coronaviru
infect
appropri
antivir
immunomodulatori
therapi
sar
merscov
infect
remain
uncertain
scarciti
qualiti
evid
absenc
good
anim
model
merscov
pose
major
challeng
mani
agent
inhibitori
activ
vitro
coronavirus
includ
licens
drug
unclear
whether
human
pharmacolog
toler
would
enabl
suffi
cient
dose
given
exert
antivir
eff
ect
patient
merscov
one
avail
drug
inhibitori
coronavirus
vitro
clinic
achiev
level
dehydrogenas
impdh
inhibitor
mycophenol
acid
anim
data
eff
ect
scarc
one
patient
develop
infect
receiv
mycophenol
mofetil
ribavirin
interferon
combin
associ
modest
centr
infectionspubl
health
englandsci
photo
librari
antivir
eff
ect
merscov
inocul
rhesu
macaqu
given
high
dose
although
clinic
relev
fi
nding
uncertain
combin
use
antivir
drug
enhanc
inhibitori
eff
ect
reduc
potenti
resist
emerg
make
sens
present
strongest
treatment
evid
support
use
convalesc
plasma
prepar
possess
neutralis
antibodi
convalesc
plasma
seem
reduc
durat
treatment
hospit
mortal
use
earli
patient
sar
merscov
low
neutralis
antibodi
respons
inabl
acquir
suffi
cient
convalesc
plasma
survivor
comorbid
might
restrict
eff
ectiv
treatment
although
limit
might
appli
infect
healthcar
worker
addit
avail
human
neutralis
monoclon
antibodi
polyclon
immun
globulin
produc
transgen
cow
host
could
overcom
hurdl
high
seropreval
hightitr
neutralis
antibodi
merscov
close
relat
viru
dromedari
camel
region
rais
possibl
use
camel
sera
engin
singl
domain
camel
antibodi
therapi
purifi
ed
immunoglobulin
immunoglobulin
fragment
nanobodi
might
er
therapeut
option
sever
ill
patient
defi
ned
genet
engin
antibodi
becom
avail
chosen
intervent
advoc
use
must
accompani
prospect
protocolbas
assess
safeti
eff
ectiv
includ
sequenti
virolog
clinic
biomark
measur
wrote
slow
acquisit
data
infl
uenza
pandem
one
outcom
circumst
format
intern
sever
acut
respiratori
emerg
infect
consortium
isar
global
feder
academ
clinic
research
network
isar
collabor
develop
biolog
sampl
protocol
applic
patient
merscov
furthermor
work
colleagu
public
health
england
isar
expert
examin
avail
data
rank
potenti
therapeut
option
regard
prioriti
clinic
studi
inform
updat
new
data
becom
avail
howev
merscov
patient
yet
enrol
therapeut
protocol
incorpor
systemat
sampl
isar
organis
consequ
learn
might
benefi
potenti
harm
patient
whatev
agent
agent
select
test
systemat
harmonis
data
collect
involv
robust
observ
studi
possibl
control
trial
need
assess
diseas
pathogenesi
candid
therapeut
merscov
clinician
public
health
offi
cial
aff
ect
middl
eastern
countri
particularli
saudi
arabia
uniqu
posit
undertak
studi
support
need
intern
partner
like
isar
region
govern
funder
middl
eastern
colleagu
opportun
respons
undertak
studi
advanc
understand
eff
ectiv
prevent
treatment
strategi
merscov
futur
novel
cov
outbreak
thu
far
merscov
yet
anoth
emerg
infect
threat
clinic
research
respons
slow
uncoordin
new
investig
framework
possibl
incorpor
mandat
intern
health
regul
urgent
need
viru
resurfac
israel
might
link
use
intraven
inactiv
polio
vaccin
ipv
transnat
mobil
also
contribut
polio
persist
circul
vaccinederiv
polioviru
cvdpv
yemen
mozambiqu
madagascar
complic
erad
eff
ort
know
spatial
distribut
polio
polio
exist
place
contain
other
detect
virul
gain
virul
mutat
threat
complex
distribut
complex
diff
usion
polioviru
associ
diff
erent
type
polio
bodi
ecolog
geopolit
realiti
polio
biomed
engin
poliovirus
ipv
degrad
version
viru
oral
polio
vaccin
opv
mutat
virus
socal
wild
polio
viru
variou
strain
bodi
polioviru
wild
polio
resist
symptomat
polio
ipv
opv
cvdpv
subclin
ecolog
vari
across
landscap
built
natur
environ
geopolit
realiti
creat
diff
erent
regulatori
structur
biomed
access
confl
ict
migrat
tension
complex
mean
erad
polio
place
peopl
certain
form
vaccin
might
possibl
immedi
futur
thu
better
imagin
diff
erent
type
virus
bodi
built
natur
ecolog
geopolit
realiti
interact
produc
present
landscap
infecti
diseas
health
geograph
argu
complex
demand
diff
erent
spatial
imaginari
concomit
vocabulari
understand
polio
set
assumpt
standard
epidemiolog
practic
suggest
control
happen
geograph
contain
particular
place
bodi
polio
contain
lead
elimin
wild
mutat
virus
particular
placesa
process
provid
promis
biomed
scienc
capac
erad
extinguish
uncontrol
form
life
although
fulli
support
eff
ort
elimin
human
suff
ere
includ
vaccin
also
believ
need
realist
capac
viru
assumpt
embed
vaccin
eff
ort
appreci
ontolog
posit
virus
circul
ecosystem
poliovirus
bound
humanli
produc
built
natur
ecolog
exist
polit
natur
boundari
interest
poliovirus
surviv
depend
abil
fi
nd
human
host
poliovirus
therefor
reli
ocularcentr
spatial
imagin
human
be
peopl
need
see
poliovirus
know
erad
control
includ
virus
use
vaccin
laboratori
studi
poliovirus
know
negoti
neg
space
human
vision
bodi
ecolog
land
scape
aff
ord
